SignalXSignalX

VCYT VERACYTE, INC.

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Services-Medical LaboratoriesSEC EDGAR
VERACYTE, INC. Overview

VERACYTE, INC. (VCYT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Impact of 2025 US federal government shutdown on operations and macroeconomic volatility, including currency fluctuations and regional conflicts (Russia-Ukraine, Israel)
  • • Updated risk: Restructuring and deconsolidation of Veracyte SAS in August 2025 causing $20.5M impairment and decline in biopharmaceutical revenue by 74% YoY Q3
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$132M

Net Income

$19M

Gross Margin

69.2%

Operating Margin

17.4%

Net Margin

14.5%

ROE

1.5%

Total Assets

$1.4B

Source: XBRL data from VERACYTE, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on VERACYTE, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.